Orthofix Medical Inc. (NASDAQ:OFIX) Given Consensus Rating of "Moderate Buy" by Analysts

Orthofix Medical Inc. (NASDAQ:OFIX - Get Free Report) has been given an average rating of "Moderate Buy" by the five brokerages that are currently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $23.33.

A number of equities research analysts have commented on the company. Stifel Nicolaus upgraded Orthofix Medical from a "hold" rating to a "buy" rating and upped their price target for the company from $18.00 to $24.00 in a research report on Friday, November 8th. Canaccord Genuity Group began coverage on Orthofix Medical in a research note on Wednesday. They issued a "buy" rating and a $24.00 price objective on the stock. Finally, Roth Mkm reissued a "buy" rating and issued a $22.00 price objective (up from $20.00) on shares of Orthofix Medical in a research note on Friday, November 8th.

Orthofix Medical Trading Down 0.5 %

Shares of NASDAQ OFIX traded down $0.10 during trading on Wednesday, reaching $18.28. The company had a trading volume of 164,161 shares, compared to its average volume of 224,719. The company's fifty day moving average price is $18.08 and its 200-day moving average price is $16.94. Orthofix Medical has a 12 month low of $12.08 and a 12 month high of $20.73. The stock has a market cap of $698.48 million, a P/E ratio of -5.84 and a beta of 1.10. The company has a quick ratio of 1.11, a current ratio of 2.39 and a debt-to-equity ratio of 0.25.

Orthofix Medical (NASDAQ:OFIX - Get Free Report) last released its quarterly earnings results on Thursday, November 7th. The medical device company reported ($0.71) EPS for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.57). Orthofix Medical had a negative net margin of 15.18% and a negative return on equity of 21.25%. The company had revenue of $196.61 million during the quarter, compared to the consensus estimate of $196.60 million. During the same quarter last year, the firm posted ($0.77) EPS. As a group, research analysts expect that Orthofix Medical will post -2.81 earnings per share for the current year.

Insider Activity

In related news, CEO Massimo Calafiore sold 9,203 shares of the company's stock in a transaction that occurred on Monday, January 13th. The stock was sold at an average price of $17.14, for a total transaction of $157,739.42. Following the transaction, the chief executive officer now directly owns 124,151 shares of the company's stock, valued at approximately $2,127,948.14. This represents a 6.90 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Julie Andrews sold 4,655 shares of the company's stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $17.89, for a total value of $83,277.95. Following the transaction, the chief financial officer now directly owns 28,312 shares in the company, valued at approximately $506,501.68. This trade represents a 14.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 24,675 shares of company stock valued at $423,238 in the last ninety days. 2.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in OFIX. American Century Companies Inc. raised its stake in Orthofix Medical by 15.7% during the 2nd quarter. American Century Companies Inc. now owns 54,964 shares of the medical device company's stock worth $729,000 after buying an additional 7,475 shares during the period. XTX Topco Ltd bought a new stake in Orthofix Medical during the 2nd quarter worth approximately $175,000. Sei Investments Co. increased its holdings in Orthofix Medical by 24.6% during the 2nd quarter. Sei Investments Co. now owns 46,195 shares of the medical device company's stock worth $613,000 after purchasing an additional 9,114 shares in the last quarter. Gabelli Funds LLC increased its holdings in Orthofix Medical by 7.9% during the 2nd quarter. Gabelli Funds LLC now owns 157,500 shares of the medical device company's stock worth $2,088,000 after purchasing an additional 11,500 shares in the last quarter. Finally, Paradigm Capital Management Inc. NY increased its holdings in Orthofix Medical by 31.3% during the 2nd quarter. Paradigm Capital Management Inc. NY now owns 2,556,100 shares of the medical device company's stock worth $33,894,000 after purchasing an additional 609,137 shares in the last quarter. 89.76% of the stock is owned by institutional investors and hedge funds.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.